Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Does the shingles vaccine Zostavax reverse the skin-specific T cell defect to varicella zoster challenge?

Next Previous
X
Search
Trial Profile

Does the shingles vaccine Zostavax reverse the skin-specific T cell defect to varicella zoster challenge?

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics

    • Most Recent Events

    • 11 Feb 2016 Accrual to date is 41% according to United Kingdom Clinical Research Network.
    • 11 Feb 2016 Planned End Date changed from 10 Oct 2017 to 31 Jan 2017, according to United Kingdom Clinical Research Network.
    • 27 Nov 2015 Planned End Date changed from 10 Oct 2015 to 10 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top